Device Trial Radar · NCT07891949
Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC)
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Oct 2026
Study completion Jun 2030
Sponsor
- Lead sponsor
- Torskal SASAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigational Device * TSK-001 injectable glucose-functionalised gold nanoparticle solution for intratumoural administration (0.3 mg nanoparticles in 1mL water for injection) * Laser device 808 nm Dose regimen TSK-001 * Part 1: Single intratumoural injection at 10%, 15%, and 20% of the tumour volume (vol/vol). * Part 2: Two intratumoural injections at the maximum tolerated dose (MTD) or maximum administered dose (MAD) administered two weeks apart. * Part 3: Two injections of TSK-001 at the Recommended Phase 2 Dose (RP2D) administered 2 weeks apart. Laser Device Near-infra red (NIR) irradiation of the tumour will be performed 1 hour after each injection of TSK-001 at the following laser settings: * Wavelength: 808 nm * Power density: 1 Watt Mode: Continuous wave * Duration: 10 minutes Comparator N/A Treatment Groups Part 1: Part 1 consists of 3 single dose escalation cohorts: * Cohort 1: TSK-001 10% vol/vol * Cohort 2: TSK-001 15% vol/vol * Cohort 3: TSK-001 20% vol/vol Part 2: Part 2 consists of a multiple dose expansion cohort who will receive two injections of TSK-001 at the MAD or MTD administered 2 weeks apart. Part 3: Part 3 consists of a Phase 2 multiple dose cohort who will receive two injections of TSK-001 at the RP2D administered 2 weeks apart. Objectives Primary Objectives Part 1 To assess the safety and tolerability of a single administration of TSK001 combined with NIR irradiation in patients with nodular Basal Cell Carcinoma (nBCC). Part 2 To assess the safety and tolerability of two administrations of TSK-001 combined with NIR irradiation in patients with nBCC. Part 3 To assess Complete Response (CR) (disappearance of cutaneous tumour) of the target lesion using RECIST v1.1 criteria following two administrations of TSK-001 combined with NIR irradiation in patients with nBCC. Secondary Objectives Part 1 * To assess the pharmacokinetics (PK) of TSK-001 in plasma and urine, and gold concentration in tumour following a single administration of TSK-001 combined with NIR irradiation in patients with nBCC. * To assess Complete Response (CR) (disappearance of cutaneous tumour) of the target lesion using RECIST v1.1 criteria following single administration of TSK-001 combined with NIR irradiation in patients with nBCC. * To assess complete clinical and imaging clearance through photography and lack of diagnostic structures on dermoscopy Part2 * To assess the pharmacokinetics (PK) of TSK-001 in plasma and urine, and gold concentration in tumour following two treatments (14 days apart) of TSK-001 combined with NIR irradiation in patients with nBCC. * To assess Complete Response (CR) (disappearance of cutaneous tumour) of the target lesion using RECIST v1.1 criteria following two administrations of TSK-001 combined with NIR irradiation in patients with nBCC. * To assess complete clinical and imaging clearance through photography and lack of diagnostic structures on dermoscopy. Part 3: * To assess complete clinical and imaging clearance through photography and lack of diagnostic structures on dermoscopy. * To assess the scar healing effect of TSK-001 combined with NIR irradiation in patients with BCC. * To assess the safety and tolerability of two administrations of TSK001 combined with NIR irradiation in patients with nBCC. * To assess the gold concentration in tumour following two administrations of TSK-001 combined with NIR irradiation in patients with nBCC. Endpoints Primary endpoints Parts 1 and 2 * Incidence, severity, and relationship of adverse events (AEs). * Changes from baseline in clinical laboratory parameters, vital signs, and 12-lead ECG. * Incidence, frequency and severity of local skin reactions (LSRs), pigmentation and scarring using the LSR Grading Scale. * Pain using a 100 mm Visual Analogic Scale (VAS) * Lesion temperature measured by infrared thermography Part 3: * CR, defined as the disappearance of the target tumour lesion according to RECIST v1.1 at Day 29. * Histology of excised residual tumour from Day 29 to Day 180. * Histology of tumour in punch biopsy at Day 180 at the latest for observation of any residual viable tumour cells after treatment. Secondary endpoints Part 1 * Plasma and urine PK parameters * Presence of gold nanoparticles in excised residual tumour at Day 29. * CR, defined as the disappearance of the target tumour lesion according to RECIST v1.1 at Day 29
Conditions
- Nodular BCC
Interventions
TSK-001. Injectable solution of glucose-functionalised plasmonic gold nanoparticles (0.3 mg in 1 mL water for injection) for intratumoural administration.Device
Investigational class III medical device: sterile, ready-to-use dispersion of glucose-coated plasmonic gold nanoparticles (0.3 mg/mL) in water for injection, without excipients, supplied in 2 mL glass vials. Administered by slow intratumoural injection (20G needle, 0.5 or 1 mL precision syringe; microinjections to avoid pocketing). The injected volume is proportional to baseline tumour volume measured by digital calliper (length × width × depth): 10%, 15% or 20% vol/vol in Part 1, MTD/MAD in Part 2, RP2D in Part 3. Single injection on Day 1 (Part 1) or two injections on Day 1 and Day 15 (Parts 2 and 3). The nanoparticles are biologically inert until activated by 808 nm near-infrared light, which they convert into localised heat.
808 nm near-infrared (NIR) diode laser (Hyper Diode 808)Device
Commercially available class IIb diode laser (Hyper Diode 808, Hyper Photonics S.r.l., Italy), used outside its labelled indications as the activation source for TSK-001. One hour after each TSK-001 injection, the target lesion is irradiated at 808 nm, 1 Watt, continuous wave, for 10 minutes. These settings are well below those used in routine dermatological applications (12-25 W) and are non-ablative in the absence of TSK-001. Lesion temperature is monitored by infrared thermography, with a target therapeutic window of 42-45 °C; a lesion temperature above 45 °C is a protocol stopping rule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- P1. Number of Participants With Treatment-Emergent Adverse Events (Parts 1 and 2)Time frame: Day 1 (D1) to Day 180
- P2. Number of Participants With Clinically Significant Laboratory Abnormalities (Parts 1 and 2)Time frame: from baseline to Day 180
- P3. Number of Participants With Clinically Significant Vital Sign Abnormalities (Parts 1 and 2)Time frame: baseline to Day 360
7 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Research Institute of New Zealand (MRINZ), Level 7, CSB Building, Wellington Hospital, Riddiford Street, Newtown, Wellington, 6021, New Zealand
Wellington, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.